KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $1.3 million.

  • Nektar Therapeutics' Change in Account Payables fell 42.84% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 44.97%. This contributed to the annual value of $2.7 million for FY2024, which is 192.51% up from last year.
  • Per Nektar Therapeutics' latest filing, its Change in Account Payables stood at $1.3 million for Q3 2025, which was up 136.38% from -$3.5 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Change in Account Payables registered a high of $7.3 million during Q4 2022, and its lowest value of -$12.9 million during Q4 2021.
  • In the last 3 years, Nektar Therapeutics' Change in Account Payables had a median value of $669,000 in 2023 and averaged $359,273.
  • As far as peak fluctuations go, Nektar Therapeutics' Change in Account Payables slumped by 552.73% in 2023, and later spiked by 748.79% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Change in Account Payables (Quarterly) stood at -$12.9 million in 2021, then soared by 156.33% to $7.3 million in 2022, then dropped by 11.57% to $6.4 million in 2023, then tumbled by 42.72% to $3.7 million in 2024, then crashed by 42.84% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$3.5 million for Q2 2025, and $6.4 million during Q1 2025.